Age is not a prognostic variable with autotransplants for multiple myeloma

Blood

Volumn 93, Issue 1, 1999, Pages 51-54

  Siegel, D S ^a   Desikan, K R ^a   Mehta, J ^a   Singhal, S ^a   Fassas, A ^a   Munshi, N ^a   Anaissie, E ^a   Naucke, S ^a   Ayers, D ^a   Spoon, D ^a   Vesole, D ^a   Tricot, G ^a   Barlogie, B ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CREATININE;

ADULT; AGE; AGED; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL;

EID: 0032908596     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.1.51.401a01_51_54     Document Type: Article

References (21)

1. Barlogie B: Plasma cell myeloma, in Beutler E, Lichtman M, Coller B, Kipps T (eds): Hematology. William's Hematology (ed 5). New York, NY, McGraw-Hill, 1995, p 1109
2. Alexanian R, Dimopoulos M: The treatment of multiple myeloma. N Engl J Med 7:484, 1994
3. Barlogie B, Jagannath S, Tricot G, Desikan KR, Fassas A, Siegel D: Advances in the treatment of multiple myeloma, in Schrier R (ed): Advances in Internal Medicine, vol 43. St Louis, MO, Mosby-Year Book, 1998, p 279
4. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335:91, 1996
5. Barlogie B, Jagannath S, Vesole D, Tricot G, Naucke S, Cheson B, Mattox S, Bracy D, Salmon S, Jacobson J, Crowley J: Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 89:789, 1997
6. Vesole DH, Barlogie B, Jagannath S, Crowley J, Cheson B, Tricot G: High dose therapy for refractory multiple myeloma: Improved prognosis with better supportive care and double transplants. Blood 84:950, 1994
7. Barlogie B, Hall R, Zander A, Dicke K, Alexanian R: High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 67:1298, 1986
8. Barlogie B, Alexanian R, Dicke KA, Zagars G, Spitzer G, Jagannath S, Horowitz L: High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 70:869, 1987
9. Vesole DH, Tricot G, Jagannath S, Desikan KR, Bracy D, Miller L, Cheson B, Crowley J, Barlogie B: Autotransplants in multiple myeloma: What have we learned? Blood 88:838, 1996
10. Tricot G, Sawyer J, Jagannath S, Bracy D, Mattox S, Vesole D, Naucke S, Barlogie B: Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 86:4250, 1995
11. Tricot G, Sawyer J, Jagannath S, Desikan KR, Siegel D, Naucke S, Mattox S, Bracy D, Munshi N, Barlogie B: The unique role of cytogenetics in the prognosis of patients with myeloma receiving high dose therapy and autotransplants. J Clin Oncol 15:2659, 1997
12. Tricot G, Jagannath S, Vesole DH, Nelson J, Tindle S, Miller L, Cheson B, Crowley J, Barlogie B: Peripheral blood stem cell transplants for multiple myeloma - Identification of favorable variables for rapid engraftment in 225 patients. Blood 85:588, 1995
13. Desikan KR, Barlogie B, Jagannath S, Vesole DH, Siegel D, Fassas A, Munshi N, Singhal S, Mehta J, Tindle S, Nelson J, Bracy D. Mattox S, Tricot G: Comparable engraftment kinetics following peripheral blood stem cell infusion mobilized with G-CSF with or without cyclophosphamide in multiple myeloma. J Clin Oncol 16:1547, 1998
14. Smith AH, Kark JD, Cassel JC, Spears GFS: Analysis of prospective epidemiologic studies by minimum distance case-control matching. Am J Epidemiol 105:567, 1997
15. Barlogie B, Alexanian R, Pershouse M, Smallwood L, Smith L: Cytoplasmic immunoglobulin content in multiple myeloma. J Clin Invest 76:765, 1985
16. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958
17. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163, 1966
18. Cox DR: Regression models and life-tables (with discussion). J R Stat Soc Series B 34:187, 1972
19. Palumbo A, Pileri A, Triolo S, Omede P, Bruno B, Cirvegna G, Galliano M, Frieri R, Boccadoro M: Multicyclic, dose-intensive chemotherapy supported by hemopoietic progenitors in refractory myeloma patients. Bone Marrow Transplant 19:23, 1997
20. Palumbo A, Pilerio A, Triolo S, Bringhen S, Rus C, Triolo R, Ravaglia R, Boccadoro M: Intensified therapy with stem cell support (MEL100) for elderly myeloma patients. Blood 90:231a, 1997 (abstr, suppl 1)
21. Tricot G, Alberts DS, Johnson CS, Roe DJ, Dorr RT, Vesole DH, Jagannath S, Meyers R, Barlogie B: Safety of autotransplants with high dose melphalan in renal failure: A pharmacokinetic and toxicity study. Clin Cancer Res 6:947, 1996